<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131387">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391546</url>
  </required_header>
  <id_info>
    <org_study_id>V211-045</org_study_id>
    <secondary_id>ZTV03C</secondary_id>
    <nct_id>NCT01391546</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Subjects Aged From 50 Years Old</brief_title>
  <official_title>An Open-label, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ZOSTAVAX When Administered by Intramuscular Route or Subcutaneous Route to Subjects of 50 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY OBJECTIVES

      Two co-primary objectives are:

        -  To demonstrate that ZOSTAVAX administered by intramuscular route (IM) is non-inferior
           to ZOSTAVAX administered by subcutaneous route (SC)

        -  To demonstrate that ZOSTAVAX administered by IM route induces an acceptable fold-rise
           of varicella zoster virus (VZV) antibody titres from pre to 4-week post-vaccination

      SECONDARY OBJECTIVES

      Immunogenicity objectives

        -  To evaluate the immunogenicity as measured by VZV antibody titres at 4 weeks following
           ZOSTAVAX administered by IM or SC route

        -  To evaluate the immune response as measured by a second assay, the VZV Interferon gamma
           Enzyme-linked immunospot (ELISPOT) at 4 weeks following ZOSTAVAX administered by IM or
           SC route

      Safety objective

      - To describe the safety profile of ZOSTAVAX administered by IM or SC route
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VZV Glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody Geometric Mean of Titres (GMT)</measure>
    <time_frame>4 week post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VZV gpELISA antibody Geometric Mean Fold Rise (GMFR) in the intramuscular arm</measure>
    <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VZV gpELISA antibody GMFR in the subcutaneous arm</measure>
    <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VZV interferon gamma ELISPOT Geometric Mean Count (GMCs)</measure>
    <time_frame>4 week post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VZV interferon gamma ELISPOT GMFR</measure>
    <time_frame>Pre-vaccination (Day 0) and 4 week post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with injection-site adverse reactions</measure>
    <time_frame>From Day 0 to Day 4 after vaccination</time_frame>
    <description>Injection-site adverse reactions: Solicited (erythema, swelling, pain) or unsolicited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with systemic adverse events</measure>
    <time_frame>From Day 0 to Day 28 after vaccination</time_frame>
    <description>Rashes of interest: i.e. Varicella, Varicella-like rashes, Herpes zoster or shingles and Herpes zoster-like rashes and other systemic adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with serious adverse events</measure>
    <time_frame>From the signature of the informed consent to 35 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">354</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>ZOSTAVAX intramuscular (IM) route</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ZOSTAVAX subcutaneous (SC) route</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1 dose at Day 0</intervention_name>
    <description>1 dose 0.65 mL</description>
    <arm_group_label>ZOSTAVAX intramuscular (IM) route</arm_group_label>
    <arm_group_label>ZOSTAVAX subcutaneous (SC) route</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged &gt;=50 years

          -  Varicella history-positive or residence for &gt;30 years in a country with endemic VZV
             infection

        Exclusion Criteria:

          -  Febrile illness

          -  History of hypersensitivity or anaphylactoid reaction to any of the vaccine
             components

          -  Prior herpes zoster episode clinically diagnosed or exposure to varicella or herpes
             zoster within the 4 weeks prior to vaccination

          -  Prior receipt of varicella or zoster vaccine

          -  Active untreated tuberculosis

          -  Thrombocytopenia, any other coagulation disorder contraindicating intramuscular
             injection

          -  Receipt of medication / vaccine that may interfere with study assessments

          -  Known or suspected immune dysfunction

          -  User of recreational / illicit drugs or subject with alcohol abuse or dependence
             within the last year

          -  Any condition that might interfere with the interpretation of the study,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 02</name>
      <address>
        <city>Dulmen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 03</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 04</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 07</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 01</name>
      <address>
        <city>Postdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 06</name>
      <address>
        <city>Riesa</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 05</name>
      <address>
        <city>Straubing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 08</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 09</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 10</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>July 7, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
